Status:
COMPLETED
A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Presently,the diagnostic method of small hepatocellular carcinoma has been greatly elevated in China.The treatment is being from simplification to diversification,from entirety to individualization.Co...
Detailed Description
randomly put in group standard: 1. via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment. 2. age: 18-70 years. 3. early hepatocyte cancer，which is sin...
Eligibility Criteria
Inclusion
- via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment.
- age:18-70years
- early hepatocyte cancer，which is single focus of infection diameter ≤3cm.
- estimate tumor can gain treatment of curing operation or micro-create treatment combineation
- better liver function (Child-Pugh，class A or B)
Exclusion
- reject to attend；
- impossible to come to our hospital for physical examination regularly.
- cancer epitome、seed focus、lymph node or distant metastasis
- Blood clotting function hindrance;
- serious heart、lung、kidney disease.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00825474
Start Date
August 1 2008
End Date
August 1 2010
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China